Login to Your Account



Financings NEWS

DUBLIN – Prexton Therapeutics SA raised €29 million in a series B round to conduct two phase II trials in Parkinson’s disease of its metabotropic glutamate receptor 4 (mGluR4) agonist, foliglurax (PXT002331).

Three-year-old Chondrial Therapeutics Inc. scored a series A financing of up to $22.6 million and licensed its first asset in a quest to build a pipeline of therapies to treat rare mitochondrial diseases.

Portola Pharmaceuticals Inc.'s CFO, Mardi Dier, told BioWorld Today the deal with HCRP was "exactly what we planned to do" – add "part two" to the "part one" of nondilutive funding late last year.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: